Friday, August 3, 2018

Toys ��R' Us Brand Auction Delay Means Santa May Not Come to Town

LISTEN TO ARTICLE 2:09 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email

A drawn-out sale process is never good for value, but in the case of Toys “R” Us, the delayed auction of its brand name could constitute an existential threat to any long-shot comeback.

That’s because the closer it gets to Christmas, the less likely any potential bidder for the chain’s intellectual property would have time to reboot the brand before the toy industry’s biggest season.

The intellectual property auction -- once expected to take place in June -- has been postponed until Oct. 4, according to recent court filings. That means a winner wouldn’t be designated until the second half of October, or several months after the wind-down of the U.S. business, which shuttered its hundreds of stores in June. In the meantime, rivals like Amazon.com Inc. and Party City Holdco Inc. have been making inroads into what was once Toys “R” Us territory.

The delay traces back to the complexity of the Toys “R” Us capital structure, according to a person with knowledge of the situation. The company’s Asia unit was paying valuable royalties to the U.S. as part of a licensing and services agreement. Now the Asian division is for sale and there is debate about whether it will continue to pay those fees or not -- an outcome that would drastically affect the unit’s value. So until the Asia unit is sold, the U.S. auction is on hold, said the person, who asked to not to be named because the negotiations are private.

If bidders for the intellectual property buy the name too late to use it for the critical holiday season, there would be little opportunity for it to generate revenue until at least 2019, driving down much of the brand’s appeal. Frequently, when a retail chain sells off its brand names and logos, little is done with them -- competitors often buy up the rights to keep them from being used by another rival -- but in this case, a bidder could be looking to resuscitate the brand.

A spokeswoman for the company declined to comment.

Former Toys Chief Executive Officer Jerry Storch, one prospective buyer of the Toys “R” Us name, has been working with investors in a bid to revive the retailer in the U.S., Bloomberg News reported in June. But a further delay in obtaining the brand could heighten existing concerns that time is too short to reconstruct the infrastructure needed to operate Toys 2.0.

— With assistance by Matthew Townsend, and Steven Church

Wednesday, August 1, 2018

Top 5 Biotech Stocks To Watch For 2019

tags:BIIB,ALNY,AMGN,ARQL,

The Republican win is an unexpected event that will ironically add to an already long list of headwinds Valeant Pharmaceuticals (NYSE:VRX) faces. Markets are now pricing in interest rate risks in the entire biotechnology sector. As interest on debt costs go up, biotech stocks in the early innings of drug development will have less money available for funding their clinical studies. Markets reacted badly to Valeant's failure to solidify a sale of Salix Pharmaceuticals to Takeda, because the $30 billion will cost more to service in the years ahead. Valeant faces headwinds from high debt levels, but investors should still anticipate the turnaround is in progress.

1/ Valeant's alternative to Salix sale

In Salix's present form, Takeda instinctively gave Valeant a low-ball offer for two reasons. First, it believed Valeant would willingly take over a billion in a goodwill write-down by selling Salix for $10 billion or less. Valeant already took a goodwill write-down in the last quarter, a move that includes some of Salix's value.

Top 5 Biotech Stocks To Watch For 2019: Biogen Idec Inc(BIIB)

Advisors' Opinion:
  • [By ]

    What should investors do with shares of Celgene (CELG) , Biogen Idec (BIIB) , Gilead Science (GILD) and Regeneron (REGN) ? Cramer once proclaimed these high-fliers his "four horsemen of biotech," but lately they've lost all of their traction, with Celgene down 21%, Biogen off 14%, Gilead down 9% and Regeneron off 23% so far this year.

  • [By Brian Feroldi]

    Data source: Alkermes. GAAP = generally accepted accounting principles.

    What happened with Alkermes this quarter? Sales of Alkermes'�opioid- and alcohol-abuse prevention drug Vivitrol grew 7% to $62.7 million. Sales of the company's�schizophrenia drug�Aristada�rose 62% to $29.2 million. Manufacturing and royalty revenue related to�Johnson & Johnson's schizophrenia drugs jumped 15% to $68.8 million. Manufacturing and royalty revenue related to�Acorda Therapeutics' multiple sclerosis drug�fell�3% to $28.3 million. Research and development revenue earned as part of its collaboration with�Biogen (NASDAQ:BIIB) for BIIB098 -- which used to be called ALKS 8700 -- was $17.5 million.

    Looking beyond the financials, here's an overview of the key events from the period:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Biogen Inc. (NASDAQ: BIIB) which traded down about 6% at 297.99. The stock��s 52-week range is $244.28 to $370.67. Volume was about 5 million compared to the daily average volume of roughly 1 million.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Biogen Inc. (NASDAQ: BIIB) which traded down nearly 4% at $329.58. The stock��s 52-week range is $244.28 to $348.84. Volume was 1.2 million matching the daily average of 1.2 million shares.

Top 5 Biotech Stocks To Watch For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:
  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn't think a few months will really matter: "We don't really feel that's going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we're very well prepared to be ready to launch following approval."

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

  • [By Logan Wallace]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

Top 5 Biotech Stocks To Watch For 2019: Amgen Inc.(AMGN)

Advisors' Opinion:
  • [By Max Byerly]

    Gables Capital Management Inc. purchased a new stake in Amgen, Inc. (NASDAQ:AMGN) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,023 shares of the medical research company’s stock, valued at approximately $174,000.

  • [By Logan Wallace]

    AlphaMark Advisors LLC cut its position in shares of Amgen (NASDAQ:AMGN) by 5.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,973 shares of the medical research company’s stock after selling 1,638 shares during the period. Amgen comprises about 2.0% of AlphaMark Advisors LLC’s investment portfolio, making the stock its 7th largest position. AlphaMark Advisors LLC’s holdings in Amgen were worth $4,769,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Intact Investment Management Inc. grew its holdings in Amgen (NASDAQ:AMGN) by 2,737.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,400 shares of the medical research company’s stock after purchasing an additional 43,800 shares during the period. Intact Investment Management Inc.’s holdings in Amgen were worth $7,739,000 as of its most recent filing with the Securities & Exchange Commission.

Top 5 Biotech Stocks To Watch For 2019: ArQule Inc.(ARQL)

Advisors' Opinion:
  • [By Cory Renauer]

    What's behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion ArQule, Inc. (NASDAQ:ARQL) 235% $482 million Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million Madrigal Pharmaceuticals, Inc.�(NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

  • [By Lisa Levin] Gainers Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy. Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings. Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS. Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter. Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625. ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday. Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results. Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94. ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07. Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50. Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000. Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64. Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90. Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock. Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55. Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

    Check out these big penny stock gainers and losers

Friday, July 20, 2018

Hot Small Cap Stocks To Invest In Right Now

tags:FCEL,PQ,CNR,ACHN,

Yesterday, our Under the Radar Movers�newsletter suggested small cap emissions solutions stock Advanced Emissions Solutions, Inc (NASDAQ: ADES) as a potential long/bullish trade:

��ADES earned a sport on out watchlist a few days ago when it broke out of a converging wedge pattern and pushed above a horizontal ceiling at $8.20. As we expected would be the case, Advanced Emissions Solutions cooled off a bit, but the rally was rekindled today with another (and even stronger) break above the $8.20 mark, on huge volume.

No new long-term positions today, though no exits either. Like we've said a few times now, we're waiting for the market to breakdown here so we can go bargain shopping. On that note...��

Hot Small Cap Stocks To Invest In Right Now: FuelCell Energy Inc.(FCEL)

Advisors' Opinion:
  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on FuelCell Energy (FCEL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Electro Scientific Industries (NASDAQ: ESIO) and FuelCell Energy (NASDAQ:FCEL) are both small-cap computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

  • [By Logan Wallace]

    FuelCell Energy (NASDAQ: FCEL) and HRG Group (NYSE:HRG) are both oils/energy companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

  • [By Shane Hupp]

    FuelCell Energy Inc (NASDAQ:FCEL) shares traded up 5.8% on Friday . The stock traded as high as $1.49 and last traded at $1.45. 12,581,855 shares traded hands during trading, an increase of 983% from the average session volume of 1,161,380 shares. The stock had previously closed at $1.37.

  • [By Shane Hupp]

    FuelCell Energy (NASDAQ: FCEL) is one of 25 public companies in the “Miscellaneous electrical machinery, equipment, & supplies” industry, but how does it contrast to its peers? We will compare FuelCell Energy to related companies based on the strength of its risk, dividends, earnings, valuation, profitability, analyst recommendations and institutional ownership.

  • [By Ethan Ryder]

    FuelCell Energy (NASDAQ: FCEL) and Integer (NYSE:ITGR) are both oils/energy companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Hot Small Cap Stocks To Invest In Right Now: Petroquest Energy Inc(PQ)

Advisors' Opinion:
  • [By Ethan Ryder]

    News headlines about Petroquest Energy (NYSE:PQ) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Petroquest Energy earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave news stories about the energy company an impact score of 47.638327846877 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Hot Small Cap Stocks To Invest In Right Now: China Metro-Rural Holdings Limited(CNR)

Advisors' Opinion:
  • [By Max Byerly]

    Canadian National Railway (NYSE:CNI) (TSE:CNR) – Cormark raised their Q3 2018 earnings per share (EPS) estimates for Canadian National Railway in a research report issued to clients and investors on Tuesday, April 10th. Cormark analyst D. Tyerman now expects that the transportation company will post earnings per share of $1.15 for the quarter, up from their previous estimate of $1.14.

  • [By Max Byerly]

    Compass Capital Management Inc. bought a new position in Canadian National Railway (NYSE:CNI) (TSE:CNR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,535 shares of the transportation company’s stock, valued at approximately $207,000.

  • [By Stephan Byrd]

    Brokerages expect Canadian National Railway (NYSE:CNI) (TSE:CNR) to announce earnings of $1.03 per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Canadian National Railway’s earnings, with the highest EPS estimate coming in at $1.10 and the lowest estimate coming in at $0.97. Canadian National Railway reported earnings of $1.00 per share in the same quarter last year, which would indicate a positive year over year growth rate of 3%. The business is scheduled to issue its next quarterly earnings report on Tuesday, July 24th.

  • [By Shane Hupp]

    Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp cut its position in Canadian National Railway (NYSE:CNI) (TSE:CNR) by 21.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,956,400 shares of the transportation company’s stock after selling 522,300 shares during the period. Canadian National Railway accounts for about 1.7% of Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s investment portfolio, making the stock its 7th biggest position. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp owned 0.27% of Canadian National Railway worth $184,215,000 at the end of the most recent reporting period.

Hot Small Cap Stocks To Invest In Right Now: Achillion Pharmaceuticals Inc.(ACHN)

Advisors' Opinion:
  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Achillion Pharmaceuticals (NASDAQ:ACHN) – Research analysts at B. Riley reduced their FY2018 EPS estimates for shares of Achillion Pharmaceuticals in a research note issued to investors on Wednesday, May 2nd. B. Riley analyst M. Kumar now anticipates that the biopharmaceutical company will earn ($0.58) per share for the year, down from their previous estimate of ($0.55). B. Riley has a “Neutral” rating and a $3.50 price objective on the stock. B. Riley also issued estimates for Achillion Pharmaceuticals’ FY2019 earnings at ($0.64) EPS, FY2020 earnings at ($0.71) EPS, FY2021 earnings at ($0.70) EPS and FY2022 earnings at ($0.84) EPS.

  • [By Lisa Levin] Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 29.4 percent to $5.50 in pre-market trading after the company disclosed that its first pivotal Phase 3 trial of IV tramadol achieved the primary and key secondary endpoints. MB Financial, Inc. (NASDAQ: MBFI) rose 16.8 percent to $51.00 in pre-market trading. Fifth Third Bancorp (NASDAQ: FITB) agreed to acquire MB Financial for $54.70 per share in cash and stock. LiveXLive Media, Inc. (NASDAQ: LIVX) rose 9.3 percent to $5.40 in pre-market trading after falling 28.92 percent on Friday. Celyad SA (NASDAQ: CYAD) shares rose 9 percent to $29.30 in pre-market trading after climbing 3.26 percent on Friday. Ethan Allen Interiors Inc. (NYSE: ETH) rose 6.7 percent to $26.40 in pre-market trading after gaining 1.64 percent on Friday. Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) rose 5.4 percent to $3.90 in pre-market trading after gaining 3.06 percent on Friday. Acacia Communications, Inc. (NASDAQ: ACIA) rose 5.2 percent to $34.70 in pre-market trading after gaining 1.38 percent on Friday. Westinghouse Air Brake Technologies Corporation (NYSE: WAB) rose 5.1 percent to $100 in pre-market trading. General Electric Company (NYSE: GE) agreed to merge its transportation unit with Wabtec. Sunrun Inc. (NASDAQ: RUN) shares rose 4.7 percent to $11.50 in pre-market trading. Nasdaq, Inc. (NASDAQ: NDAQ) shares rose 4.3 percent to $93.98 in the pre-market trading session. LaSalle Hotel Properties (NYSE: LHO) shares rose 4.2 percent to $33.25 in pre-market trading. Blackstone Group LP (NYSE: BX) will buy LaSalle Hotel Properties in a $4.8 billion deal, Bloomberg reported. Monro, Inc. (NASDAQ: MNRO) shares rose 4 percent to $58.35 in pre-market trading as the company posted upbeat quarterly earnings and disclosed that it has acquired Free Service Tire. HUYA Inc. (NYSE: HUYA) rose 3.7 percent to $19.75 in pre-market trading after falling 4.80 percent on Friday.

    Find out what's going

  • [By Stephan Byrd]

    Achillion Pharmaceuticals (NASDAQ:ACHN) has been given an average recommendation of “Hold” by the nine brokerages that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $5.20.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    News articles about Achillion Pharmaceuticals (NASDAQ:ACHN) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.941587509483 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Wednesday, July 11, 2018

Bytecoin (BCN) Market Capitalization Hits $550.44 Million

Bytecoin (CURRENCY:BCN) traded down 6.2% against the US dollar during the 24 hour period ending at 13:00 PM Eastern on July 9th. Bytecoin has a total market capitalization of $550.44 million and $7.57 million worth of Bytecoin was traded on exchanges in the last day. One Bytecoin coin can currently be bought for approximately $0.0030 or 0.00000045 BTC on major cryptocurrency exchanges including Stocks.Exchange, Binance, Poloniex and cfinex. In the last seven days, Bytecoin has traded 14.3% lower against the US dollar.

Here’s how related cryptocurrencies have performed in the last day:

Get Bytecoin alerts: Monero (XMR) traded 1.4% lower against the dollar and now trades at $137.18 or 0.02047640 BTC. DigitalNote (XDN) traded up 0.9% against the dollar and now trades at $0.0061 or 0.00000091 BTC. Aeon (AEON) traded 3.4% lower against the dollar and now trades at $1.27 or 0.00019009 BTC. Boolberry (BBR) traded 1.9% lower against the dollar and now trades at $0.91 or 0.00013560 BTC. Interplanetary Broadcast Coin (IPBC) traded up 2.6% against the dollar and now trades at $0.18 or 0.00002206 BTC. Sumokoin (SUMO) traded up 32.8% against the dollar and now trades at $0.77 or 0.00011472 BTC. Karbo (KRB) traded down 4.2% against the dollar and now trades at $0.35 or 0.00005147 BTC. IntenseCoin (ITNS) traded 3.7% lower against the dollar and now trades at $0.0024 or 0.00000036 BTC. Stellite (XTL) traded 14.9% lower against the dollar and now trades at $0.0003 or 0.00000005 BTC. LeviarCoin (XLC) traded 13.5% lower against the dollar and now trades at $0.0776 or 0.00000823 BTC.

Bytecoin Profile

Bytecoin is a proof-of-work (PoW) coin that uses the Cryptonight hashing algorithm. Its genesis date was July 4th, 2012. Bytecoin’s total supply is 183,890,481,254 coins. The Reddit community for Bytecoin is /r/BytecoinBCN and the currency’s Github account can be viewed here. The official message board for Bytecoin is bytecointalk.org. The official website for Bytecoin is bytecoin.org. Bytecoin’s official Twitter account is @Bytecoin_BCN and its Facebook page is accessible here.

Buying and Selling Bytecoin

Bytecoin can be purchased on the following cryptocurrency exchanges: cfinex, TradeOgre, Vebitcoin, HitBTC, Crex24, Poloniex, Binance and Stocks.Exchange. It is usually not currently possible to buy alternative cryptocurrencies such as Bytecoin directly using U.S. dollars. Investors seeking to trade Bytecoin should first buy Ethereum or Bitcoin using an exchange that deals in U.S. dollars such as Coinbase, Changelly or Gemini. Investors can then use their newly-acquired Ethereum or Bitcoin to buy Bytecoin using one of the exchanges listed above.

new TradingView.widget({ “height”: 400, “width”: 650, “symbol”: “BCNUSD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Tuesday, July 10, 2018

General Motors to Post FY2018 Earnings of $6.33 Per Share, Jefferies Financial Group Forecasts (GM)

General Motors (NYSE:GM) (TSE:GMM.U) – Jefferies Financial Group issued their FY2018 earnings per share (EPS) estimates for shares of General Motors in a research report issued to clients and investors on Thursday, July 5th. Jefferies Financial Group analyst P. Houchois anticipates that the auto manufacturer will earn $6.33 per share for the year. Jefferies Financial Group also issued estimates for General Motors’ FY2019 earnings at $6.40 EPS.

Get General Motors alerts:

General Motors (NYSE:GM) (TSE:GMM.U) last announced its quarterly earnings data on Thursday, April 26th. The auto manufacturer reported $1.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.19. The business had revenue of $36.10 billion for the quarter, compared to the consensus estimate of $34.67 billion. General Motors had a negative net margin of 3.76% and a positive return on equity of 23.03%. General Motors’s quarterly revenue was down 12.4% on a year-over-year basis. During the same quarter last year, the company posted $1.70 earnings per share.

Several other equities research analysts also recently issued reports on GM. JPMorgan Chase & Co. restated an “overweight” rating and issued a $55.00 price objective (down previously from $56.00) on shares of General Motors in a research note on Tuesday, March 13th. Morgan Stanley reiterated an “equal weight” rating and set a $45.00 price target (up previously from $44.00) on shares of General Motors in a research note on Wednesday, March 14th. Goldman Sachs Group reiterated a “sell” rating and set a $31.00 price target on shares of General Motors in a research note on Wednesday, March 28th. TheStreet downgraded shares of General Motors from a “b” rating to a “c+” rating in a research note on Tuesday, March 27th. Finally, Vetr downgraded shares of General Motors from a “strong-buy” rating to a “buy” rating and set a $41.50 price target on the stock. in a research note on Thursday, April 5th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $47.45.

Shares of General Motors opened at $39.75 on Monday, Marketbeat.com reports. The firm has a market capitalization of $55.19 billion, a PE ratio of 6.00, a P/E/G ratio of 1.11 and a beta of 1.65. The company has a debt-to-equity ratio of 1.96, a quick ratio of 0.73 and a current ratio of 0.86. General Motors has a 1 year low of $34.50 and a 1 year high of $46.76.

Large investors have recently modified their holdings of the company. Stelac Advisory Services LLC bought a new position in shares of General Motors in the first quarter valued at about $119,000. Pinnacle Financial Partners Inc. bought a new position in shares of General Motors in the first quarter valued at about $141,000. Advisors Preferred LLC raised its holdings in shares of General Motors by 407.7% in the first quarter. Advisors Preferred LLC now owns 3,904 shares of the auto manufacturer’s stock valued at $142,000 after buying an additional 3,135 shares during the last quarter. Knott David M bought a new position in shares of General Motors in the first quarter valued at about $182,000. Finally, Fieldpoint Private Securities LLC bought a new position in shares of General Motors in the first quarter valued at about $184,000. Institutional investors own 73.30% of the company’s stock.

In other news, EVP Alan S. Batey sold 215,685 shares of the business’s stock in a transaction on Friday, June 1st. The shares were sold at an average price of $43.01, for a total value of $9,276,611.85. Following the sale, the executive vice president now owns 84,594 shares in the company, valued at approximately $3,638,387.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.39% of the stock is currently owned by insiders.

The company also recently announced a quarterly dividend, which was paid on Friday, June 22nd. Stockholders of record on Friday, June 8th were paid a $0.38 dividend. The ex-dividend date of this dividend was Thursday, June 7th. This represents a $1.52 annualized dividend and a dividend yield of 3.82%. General Motors’s dividend payout ratio is presently 22.96%.

About General Motors

General Motors Company, together with its subsidiaries, designs, builds, and sells cars, trucks, crossovers, and automobile parts worldwide. The company operates through GM North America, GM International, and GM Financial segments. It markets its vehicles primarily under the Buick, Cadillac, Chevrolet, GMC, Holden, Baojun, Jiefang, and Wuling brand names.

Earnings History and Estimates for General Motors (NYSE:GM)

Friday, July 6, 2018

Bed, Bath and Beyond's Comps Took a Dip; BJ's New Shares Jumped Higher

For this segment from the Motley Fool Money podcast, it's a tale of two retailers -- one enjoying the best of times, and one having a rougher go of things. Host Chris Hill and senior Motley Fool analysts Jason Moser, Matt Argersinger, and Ron Gross start with the bad news first: Housewares specialist Bed Bath & Beyond (NASDAQ:BBBY) met its revenue targets, but a slump in same-store sales spooked investors, at least temporarily. The Fools' consensus is that this is not a stock you want in your portfolio -- but there's one possible catalyst that could help the company change course.

On the good news front, BJ's Wholesale Club (NYSE:BJ), which was taken private in 2011, returned to the public markets last week, and its shares took a healthy jump from their initial public offering price. The situation is certainly a win for the private-equity players who owned it, and who still own a majority. But again, the question for Fools is: Would you be well-advised to join them?

A full transcript follows the video.

This video was recorded on June 29, 2018.

Chris Hill: First quarter revenue for Bed Bath & Beyond was about what analysts were expecting, but same-store sales were negative. Shares of Bed Bath & Beyond down 10% on Thursday. Although, Jason, they do appear to have recovered from that.

Jason Moser: See, Chris, your statement right there, it's kind of like, I'm trying to find the light at the end of the tunnel. I want to be a glass-half-full guy.

Ron Gross: I don't believe you.

Moser: [laughs] When it comes to Bed Bath & Beyond, I truly can't think of one reason why you would want to own this stock. There are just so many challenges the business is facing. Top line growth is anemic, comps are down, they're still buying back shares with a net debt position. It's a very difficult space to be in these days, bricks-and-mortar retail. They've spent more than $5.5 billion on shares repurchases since 2014, and all the while, the stock price is down 75% over that same course of time. That's the George Costanza, man! That's the opposite! You don't want to be doing that!

Now, there is, potentially, a catalyst that could help the business with their new Beyond+ loyalty program. It's a membership program, you pay $29 a year, you get deals in store, free shipping on qualified items. That's reducing the amount of couponing. What remains to be seen is if this is a program that can actually gain traction, keep members, and then renew members. Does it mean you want to own the stock? I don't think so.

Matt Argersinger: Wait, if I sign up for that program, will I stop getting the 20% off blue coupons in my mail every day?

Moser: See, that's where I'm not totally clear.

Gross: You'll probably still get them, but you can throw them away.

Moser: It's like, you can't stop the mail, right? That stuff, I think, is still going to come your way. But maybe you won't have to actually go to the store and use them, you could buy online, or you could go to the store and just present your membership card.

Hill: Is the loyalty program brand new? Or has this been going on? Do you have any sense of how many people are already in it?

Moser: I do not have a sense of how many people are in it. If you look at the website, they actually still classify it as a beta program. The inception started a couple of years back. Still very new program. They're learning a lot from in.

Honestly, I think, you look at something like Restoration Hardware, they tried the same thing. It seems like it's given them another lease on life. Perhaps that'll play out for Bed Bath & Beyond that way, too. But still, a lot to be seen.

Hill: I'm glad you mentioned that because that's what I was thinking of. When Restoration Hardware announced that loyalty program, I think we all looked around the table and said, "There's no way this is actually going to work, is it?" And that's actually paid off for them.

Moser: It's paid off so far. The big question is, can it sustain those renewals? Will people continue to renew as time goes on? That's what Amazon Prime has done so well, that's what Costco has done so well. Restoration Hardware, Bed Bath & Beyond, I'm not sure they have the same place in the consumer's day-to-day shopping experience. That's the question mark.

Gross: RH also revamped their stores, the look and feel and even the merchandising of them, whereas Bed Bath is just a cluster. You walk in there -- I don't know who designed those carts that you can't even push down the aisle. The shopping experience is not perfect.

Hill: At least one bricks and mortar retail stock had a good week. BJ's Wholesale Club was taken private in 2011. It's now back as a public company and shares up 30% on the first day of trading for BJ's Wholesale. Ron, you buying?

Gross: It's like Costco, but not as big and not as good.

Moser: [laughs] I'm going to say that's a maybe?

Gross: If you want to get into the private equity game, this is a good deal: you take a company private at $2.8 billion at around 6-7 times earnings. You take $2 billion of dividends out of it while it's private, then you take it back public at a similar valuation, which is, however, now 40 times earnings, and you retain 69% of the stock. If you can get that, I say, get that.

But, as far as differentiating itself from the Costcos and the Sam's Clubs of the world, it really doesn't. It's a very similar business model, which actually is a good business model. The membership fees in this particular case amount to about 52% of the company's EBITDA. That's nice recurring revenue, nothing wrong with that.

But, it's quite small compared to the competitors. They have about five million numbers, vs. Costco, which has about 51 million members. They have about 215 clubs, where Costco has 750 clubs. So, maybe, the glass half-full, Jason over there, would say there's plenty of room for growth, but I think it's just a very competitive space.

Moser: It's very funny, the feelings that brands elicit. The only real experience I had with BJ's was back in 2005, 2006, when we were in Atlanta, and we were getting ready to go to Kazakhstan for a two-year post there. We had to bring diapers for two infants for basically two years. So, we made a week's worth of runs to BJ's Wholesale and would walk out with four boxes of diapers every day, until our garage was actually stacked to the ceiling with boxes of diapers. The neighbors were beside themselves, thinking we were running some kind of black market for diapers or something.

Thursday, July 5, 2018

Honeywell International Inc. Has $29.83 Million Position in Apple Inc. (AAPL)

Honeywell International Inc. decreased its position in shares of Apple Inc. (NASDAQ:AAPL) by 54.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 177,800 shares of the iPhone maker’s stock after selling 214,800 shares during the period. Apple comprises 1.7% of Honeywell International Inc.’s holdings, making the stock its 11th largest holding. Honeywell International Inc.’s holdings in Apple were worth $29,831,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Smart Portfolios LLC acquired a new stake in Apple in the first quarter valued at approximately $134,000. Oak Point Wealth Management acquired a new stake in Apple in the fourth quarter valued at approximately $163,000. Stuart Chaussee & Associates Inc. boosted its position in Apple by 940.8% in the fourth quarter. Stuart Chaussee & Associates Inc. now owns 1,072 shares of the iPhone maker’s stock valued at $181,000 after buying an additional 969 shares in the last quarter. Interactive Financial Advisors acquired a new stake in Apple in the fourth quarter valued at approximately $188,000. Finally, Delphi Private Advisors LLC boosted its position in Apple by 8,292.9% in the fourth quarter. Delphi Private Advisors LLC now owns 1,175 shares of the iPhone maker’s stock valued at $199,000 after buying an additional 1,161 shares in the last quarter. Institutional investors and hedge funds own 58.07% of the company’s stock.

Get Apple alerts:

Apple stock opened at $183.92 on Wednesday. Apple Inc. has a fifty-two week low of $142.41 and a fifty-two week high of $194.20. The stock has a market cap of $949.75 billion, a P/E ratio of 18.07, a PEG ratio of 1.54 and a beta of 1.24. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.37 and a current ratio of 1.46.

Apple (NASDAQ:AAPL) last released its earnings results on Tuesday, May 1st. The iPhone maker reported $2.73 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.69 by $0.04. The firm had revenue of $61.14 billion for the quarter, compared to analysts’ expectations of $60.94 billion. Apple had a net margin of 21.55% and a return on equity of 39.97%. The company’s quarterly revenue was up 15.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.10 earnings per share. research analysts anticipate that Apple Inc. will post 11.42 earnings per share for the current year.

Apple declared that its board has authorized a share buyback plan on Tuesday, May 1st that authorizes the company to repurchase $100.00 billion in outstanding shares. This repurchase authorization authorizes the iPhone maker to repurchase up to 11.9% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

AAPL has been the topic of a number of research analyst reports. Maxim Group upgraded shares of Apple from a “hold” rating to a “buy” rating in a research report on Thursday, May 31st. Morgan Stanley cut their target price on shares of Apple from $203.00 to $200.00 and set an “overweight” rating on the stock in a research report on Friday, April 20th. Monness Crespi & Hardt initiated coverage on shares of Apple in a research report on Wednesday, April 11th. They issued a “buy” rating and a $235.00 target price on the stock. Royal Bank of Canada set a $203.00 price target on shares of Apple and gave the company a “buy” rating in a research note on Wednesday, April 11th. Finally, Goldman Sachs Group set a $159.00 price target on shares of Apple and gave the company a “neutral” rating in a research note on Tuesday, April 3rd. One analyst has rated the stock with a sell rating, sixteen have issued a hold rating, thirty-one have issued a buy rating and two have given a strong buy rating to the stock. Apple has a consensus rating of “Buy” and a consensus target price of $207.20.

In other Apple news, SVP Daniel J. Riccio sold 17,372 shares of the business’s stock in a transaction dated Thursday, May 17th. The shares were sold at an average price of $187.64, for a total value of $3,259,682.08. Following the transaction, the senior vice president now directly owns 43,644 shares in the company, valued at $8,189,360.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Jeffrey E. Williams sold 15,653 shares of the business’s stock in a transaction dated Friday, June 8th. The shares were sold at an average price of $190.94, for a total transaction of $2,988,783.82. Following the completion of the transaction, the chief operating officer now owns 147,819 shares in the company, valued at $28,224,559.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 192,208 shares of company stock worth $35,104,302. Corporate insiders own 0.06% of the company’s stock.

Apple Profile

Apple Inc designs, manufactures, and markets mobile communication and media devices, and personal computers to consumers, and small and mid-sized businesses; and education, enterprise, and government customers worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.

Want to see what other hedge funds are holding AAPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apple Inc. (NASDAQ:AAPL).

Institutional Ownership by Quarter for Apple (NASDAQ:AAPL)

Wednesday, July 4, 2018

Brokerages Set KLA-Tencor Corp (KLAC) Price Target at $131.69

Shares of KLA-Tencor Corp (NASDAQ:KLAC) have been given a consensus recommendation of “Buy” by the seventeen analysts that are currently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $131.69.

A number of analysts have recently issued reports on the company. Zacks Investment Research raised KLA-Tencor from a “hold” rating to a “buy” rating and set a $117.00 price target on the stock in a research note on Wednesday, June 27th. BidaskClub lowered KLA-Tencor from a “buy” rating to a “hold” rating in a research note on Thursday, June 21st. Citigroup lifted their price target on KLA-Tencor from $122.00 to $127.00 and gave the stock a “buy” rating in a research note on Monday, April 30th. Needham & Company LLC lowered KLA-Tencor from a “buy” rating to a “hold” rating in a research note on Friday, June 22nd. Finally, Cowen assumed coverage on KLA-Tencor in a research note on Monday, May 14th. They issued an “outperform” rating and a $140.00 price target on the stock.

Get KLA-Tencor alerts:

Institutional investors have recently made changes to their positions in the stock. Deutsche Bank AG lifted its position in KLA-Tencor by 3.2% during the fourth quarter. Deutsche Bank AG now owns 1,322,056 shares of the semiconductor company’s stock worth $138,902,000 after buying an additional 40,512 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in KLA-Tencor by 52.3% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,066 shares of the semiconductor company’s stock worth $742,000 after buying an additional 2,425 shares in the last quarter. MANA Advisors LLC purchased a new position in KLA-Tencor during the fourth quarter worth approximately $725,000. Geode Capital Management LLC lifted its position in KLA-Tencor by 11.1% during the fourth quarter. Geode Capital Management LLC now owns 2,184,792 shares of the semiconductor company’s stock worth $229,185,000 after buying an additional 218,032 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new position in KLA-Tencor during the fourth quarter worth approximately $3,110,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

KLAC traded down $2.20 during trading on Friday, hitting $101.60. The company’s stock had a trading volume of 803,832 shares, compared to its average volume of 1,497,752. The company has a current ratio of 3.78, a quick ratio of 3.07 and a debt-to-equity ratio of 1.80. KLA-Tencor has a twelve month low of $87.93 and a twelve month high of $123.96. The firm has a market cap of $16.18 billion, a P/E ratio of 17.10, a PEG ratio of 0.72 and a beta of 1.53.

KLA-Tencor (NASDAQ:KLAC) last issued its quarterly earnings data on Thursday, April 26th. The semiconductor company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.99 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. KLA-Tencor had a return on equity of 86.87% and a net margin of 18.17%. KLA-Tencor’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same period last year, the company earned $1.62 earnings per share. equities research analysts forecast that KLA-Tencor will post 7.93 EPS for the current year.

KLA-Tencor declared that its Board of Directors has approved a share buyback program on Monday, March 19th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the semiconductor company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board believes its stock is undervalued.

KLA-Tencor Company Profile

KLA-Tencor Corporation designs, manufactures, and markets process control and yield management solutions for the semiconductor and related nano-electronics industries worldwide. It offers chip manufacturing products, such as front-end defect inspection tools, defect review systems, advanced packaging process control systems, metrology solutions, in-situ process monitoring products, and lithography software; wafer manufacturing products comprising wafer manufacturing products comprising surface and defect inspection, wafer geometry and nanotopography metrology, and data management; and reticle manufacturing products, such as defect inspection and pattern placement metrology products.

Analyst Recommendations for KLA-Tencor (NASDAQ:KLAC)

Monday, June 25, 2018

Will Bed Bath & Beyond Return to Sales Growth on Thursday?

Bed Bath & Beyond�(NASDAQ:BBBY)�will kick off its fiscal 2018 year on June 27 with its fiscal first-quarter earnings report set to publish after the market closes. The fact that its stock recently touched a 10-year low suggests that investors aren't expecting much good news from the specialty retailer. Its last fiscal year, after all, was marked by declining sales and reduced profitability as customers chose other places, especially online providers, to fill their home furnishing needs.

Those negative trends aren't likely to have changed in the last few months, but Bed Bath & Beyond might have a few surprises for shareholders on Thursday.

A busy shopping mall.

Image source: Getty Images.

Sales growth

The biggest disappointment in Bed Bath & Beyond's latest fiscal year was its sales performance. Customer traffic trends were negative in 2017, and that headwind more than offset modest growth in the online business to send comparable-store sales lower by 1.3%. That result marked the second straight year of negative sales at existing locations and was a slight worsening from the prior year's 0.6% drop.

Yet CEO Steven Temares and his executive team said in April that the worst is likely behind them. In fact, they expect the company to return to sales growth in the new fiscal year with help from an expanding economy and a range of improvements that they're making to their merchandising, pricing, and online selling strategies. Bed Bath & Beyond will have to support that optimistic forecast with numbers in this report that show firmer sales trends in both its online and physical selling channels.

Profit margins

The news isn't much better on profitability, as gross profit margin fell for its second straight year in 2017, dropping to 36% of sales from 37.5%. At the same time, Bed Bath & Beyond spent more cash on things like wages and advertising, and on building out its online sales channel. As a result, operating profit margin for the year dived to 6.2% of sales, compared to 9.3% in 2016. It was nearly 12% of sales in fiscal 2015.

Executives made optimistic comments about their profitability position back in April, saying that the 6% decline in inventory that they managed last year left the company in good shape for 2018. The stores are packed with products that are "tailored to meet the anticipated demands our customers," CFO Sue Lattmann said in a conference call.

Thus, investors will be watching trends in gross profit margin for signs that the leaner inventory position is actually helping lift results. Another weak quarterly outing on this score, meanwhile, would confirm many investors' fears that Bed Bath & Beyond is facing bigger, more fundamental challenges to its operating model.

A low bar to clear

The retailer issued a painful earnings forecast in April. This prediction sees operating margins and earnings per share falling in fiscal 2018 and fiscal 2019, although executives hope that the pace of declines will moderate over that time. This means shareholders are being asked to wait until after the company completes its fourth consecutive year of falling profits before an earnings rebound can take place starting in 2020. �

The fact that this forecast is already so bleak suggests it will be hard for Bed Bath & Beyond to shock investors with unexpected bad news on Thursday. That scenario is still possible, though, considering that executives have projected improving sales and gross profit trends in the new fiscal year, which might not materialize.

Sunday, June 24, 2018

Mercury Reaches 24 Hour Trading Volume of $98,606.00 (MER)

Mercury (CURRENCY:MER) traded 5.6% lower against the U.S. dollar during the 24-hour period ending at 23:00 PM Eastern on June 22nd. One Mercury token can currently be purchased for approximately $0.12 or 0.00002029 BTC on popular cryptocurrency exchanges including Tidex, Upbit, Waves Decentralized Exchange and Bittrex. Mercury has a market capitalization of $12.41 million and $98,606.00 worth of Mercury was traded on exchanges in the last day. During the last week, Mercury has traded down 6.8% against the U.S. dollar.

Here’s how similar cryptocurrencies have performed during the last day:

Get Mercury alerts: XRP (XRP) traded 6.7% lower against the dollar and now trades at $0.52 or 0.00008331 BTC. Ripple (XRP) traded down 6.8% against the dollar and now trades at $0.49 or 0.00008034 BTC. Stellar (XLM) traded 9.5% lower against the dollar and now trades at $0.20 or 0.00003320 BTC. TRON (TRX) traded 8.2% lower against the dollar and now trades at $0.0437 or 0.00000715 BTC. IOTA (MIOTA) traded down 11.8% against the dollar and now trades at $1.00 or 0.00016334 BTC. Tether (USDT) traded 0.1% higher against the dollar and now trades at $1.00 or 0.00016402 BTC. NEO (NEO) traded 9% lower against the dollar and now trades at $33.59 or 0.00549413 BTC. Binance Coin (BNB) traded down 6.6% against the dollar and now trades at $15.58 or 0.00254864 BTC. VeChain (VET) traded down 9.5% against the dollar and now trades at $2.83 or 0.00046228 BTC. Ontology (ONT) traded 15% lower against the dollar and now trades at $5.23 or 0.00085468 BTC.

Mercury Profile

Mercury’s launch date was March 15th, 2017. Mercury’s total supply is 100,000,000 tokens. Mercury’s official Twitter account is @darcrus and its Facebook page is accessible here. Mercury’s official website is www.darcr.us.

Mercury Token Trading

Mercury can be purchased on the following cryptocurrency exchanges: Tidex, Bittrex, Upbit and Waves Decentralized Exchange. It is usually not presently possible to buy alternative cryptocurrencies such as Mercury directly using US dollars. Investors seeking to acquire Mercury should first buy Ethereum or Bitcoin using an exchange that deals in US dollars such as Changelly, Gemini or GDAX. Investors can then use their newly-acquired Ethereum or Bitcoin to buy Mercury using one of the exchanges listed above.

new TradingView.widget({ “height”: 400, “width”: 650, “symbol”: “MERUSD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Wednesday, June 20, 2018

Actuant Co. (ATU) Expected to Announce Quarterly Sales of $305.93 Million

Equities analysts expect Actuant Co. (NYSE:ATU) to post $305.93 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Actuant’s earnings, with the highest sales estimate coming in at $308.52 million and the lowest estimate coming in at $303.04 million. Actuant posted sales of $295.43 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.6%. The business is scheduled to report its next earnings results before the market opens on Wednesday, June 20th.

According to Zacks, analysts expect that Actuant will report full year sales of $1.15 billion for the current financial year, with estimates ranging from $1.14 billion to $1.16 billion. For the next financial year, analysts expect that the company will post sales of $1.20 billion per share, with estimates ranging from $1.19 billion to $1.20 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Actuant.

Get Actuant alerts:

Actuant (NYSE:ATU) last announced its quarterly earnings results on Wednesday, March 21st. The industrial products company reported $0.13 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by ($0.01). Actuant had a positive return on equity of 9.21% and a negative net margin of 7.86%. The business had revenue of $275.20 million for the quarter, compared to analyst estimates of $267.57 million. During the same quarter last year, the company earned $0.11 EPS. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year.

A number of research analysts recently issued reports on the stock. Stifel Nicolaus lowered their target price on shares of Actuant from $26.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, March 22nd. Robert W. Baird reiterated a “buy” rating and issued a $25.00 target price on shares of Actuant in a research note on Thursday, March 22nd. BMO Capital Markets lowered their target price on shares of Actuant from $25.00 to $24.00 and set a “market perform” rating on the stock in a research note on Thursday, March 22nd. Zacks Investment Research upgraded shares of Actuant from a “sell” rating to a “hold” rating in a research note on Wednesday, May 30th. Finally, KeyCorp lowered their target price on shares of Actuant from $29.00 to $27.00 and set an “overweight” rating on the stock in a research note on Thursday, March 22nd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $24.44.

In related news, Director Alfredo Altavilla purchased 2,000 shares of Actuant stock in a transaction on Monday, May 14th. The stock was purchased at an average cost of $24.75 per share, with a total value of $49,500.00. Following the acquisition, the director now directly owns 2,000 shares in the company, valued at $49,500. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 1.10% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of ATU. Schwab Charles Investment Management Inc. boosted its holdings in Actuant by 7.2% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 548,829 shares of the industrial products company’s stock valued at $13,886,000 after purchasing an additional 36,778 shares during the period. Teacher Retirement System of Texas bought a new stake in Actuant in the 4th quarter valued at $516,000. California Public Employees Retirement System boosted its holdings in Actuant by 6.6% in the 4th quarter. California Public Employees Retirement System now owns 200,057 shares of the industrial products company’s stock valued at $5,061,000 after purchasing an additional 12,363 shares during the period. Wells Fargo & Company MN boosted its holdings in Actuant by 16.7% in the 4th quarter. Wells Fargo & Company MN now owns 283,153 shares of the industrial products company’s stock valued at $7,164,000 after purchasing an additional 40,578 shares during the period. Finally, Arizona State Retirement System boosted its holdings in Actuant by 224.9% in the 4th quarter. Arizona State Retirement System now owns 100,542 shares of the industrial products company’s stock valued at $2,544,000 after purchasing an additional 69,597 shares during the period.

Actuant traded up $0.05, reaching $25.95, during midday trading on Friday, Marketbeat Ratings reports. The stock had a trading volume of 446,100 shares, compared to its average volume of 461,422. Actuant has a 1-year low of $21.50 and a 1-year high of $27.95. The company has a current ratio of 2.15, a quick ratio of 1.55 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $1.55 billion, a PE ratio of 30.66, a PEG ratio of 2.69 and a beta of 1.48.

About Actuant

Actuant Corporation designs, manufactures, and distributes a range of industrial products and systems worldwide. It operates through three segments: Industrial, Energy, and Engineered Solutions. The Industrial segment is primarily involved in the design, manufacture, and distribution of branded hydraulic and mechanical tools to the maintenance, industrial, infrastructure, and production automation markets under the Enerpac, Larzep, Milwaukee Cylinder, Precision-Hayes, and Simplex brand names.

Get a free copy of the Zacks research report on Actuant (ATU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Actuant (NYSE:ATU)

Wednesday, May 30, 2018

Top 10 Heal Care Stocks To Invest In Right Now

tags:GABC,APTS,COTV,BBRY,EDU,MDGL,OIS,CNSL,SNE,MHVYF,

In case you haven't noticed, there has been a great deal of strength in the stock market during the past month. But the rebound isn��t coming from the market leaders of the past several years. The high-flying growth stocks, especially in the tech sector, and the petroleum and resource stocks that once enjoyed great popularity have let many people down in recent months.

See Also: 8 Great Dividend Stocks for Retirees

What is holding up well are the mundane stocks that many consider too boring to own, such as food, utilities, and other consumer staples that represent the needs rather than the wants of the population. These are just the type of stocks that we have always highlighted in relation to dividend reinvestment plans (DRIPs), a form of investing that was created out of the strength of well-known consumer brands companies like Procter & Gamble, Colgate-Palmolive and Kimberly-Clark, along with diversified industrials like 3M Company, Boeing and Raytheon. Even in the oil sector, the size and resources of Exxon Mobil make it stand out in sharp contrast to the master limited partnerships (MLPs) that have been decimated.

Top 10 Heal Care Stocks To Invest In Right Now: German American Bancorp, Inc.(GABC)

Advisors' Opinion:
  • [By Logan Wallace]

    German American Bancorp, Inc. (NASDAQ:GABC) – Research analysts at FIG Partners increased their FY2018 earnings estimates for German American Bancorp in a research report issued to clients and investors on Wednesday, May 2nd. FIG Partners analyst B. Martin now anticipates that the bank will post earnings of $2.02 per share for the year, up from their prior estimate of $2.00.

Top 10 Heal Care Stocks To Invest In Right Now: Preferred Apartment Communities, Inc.(APTS)

Advisors' Opinion:
  • [By Joseph Griffin]

    Preferred Apartment (NYSE:APTS) – Research analysts at B. Riley raised their FY2018 earnings estimates for shares of Preferred Apartment in a note issued to investors on Thursday, May 3rd. B. Riley analyst C. Kucera now expects that the real estate investment trust will post earnings per share of $1.45 for the year, up from their prior estimate of $1.44. B. Riley currently has a “Hold” rating and a $16.00 price target on the stock. B. Riley also issued estimates for Preferred Apartment’s Q4 2018 earnings at $0.40 EPS.

Top 10 Heal Care Stocks To Invest In Right Now: Cotiviti Holdings, Inc. (COTV)

Advisors' Opinion:
  • [By Max Byerly]

    Cotiviti Holdings, Inc. (NYSE:COTV) – Equities research analysts at Jefferies Group lowered their FY2018 earnings estimates for Cotiviti in a report issued on Wednesday, May 2nd. Jefferies Group analyst S. Dodge now expects that the business services provider will post earnings per share of $1.68 for the year, down from their previous estimate of $1.71. Jefferies Group also issued estimates for Cotiviti’s FY2019 earnings at $1.87 EPS.

Top 10 Heal Care Stocks To Invest In Right Now: BlackBerry Limited(BBRY)

Advisors' Opinion:
  • [By Shane Hupp]

    BlackBerry (TSE:BB) (NASDAQ:BBRY)‘s stock had its “in-line” rating reiterated by analysts at Imperial Capital in a report issued on Wednesday.

Top 10 Heal Care Stocks To Invest In Right Now: New Oriental Education & Technology Group, Inc.(EDU)

Advisors' Opinion:
  • [By Lisa Levin] Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares rose 35.8 percent to $4.55. EVINE Live Inc. (NASDAQ: EVLV) gained 28.8 percent to $1.04. The pay-TV home shopping company was named as a potential acquisition target by TechCrunch. According to the publication, Amazon.com, Inc. (NASDAQ: AMZN) is exploring ways of marketing its products and services to consumers beyond the internet. Sanmina Corp (NASDAQ: SANM) shares surged 19.1 percent to $33.00 as the company reported stronger-than-expected earnings for its second quarter on Monday. Heidrick & Struggles International, Inc. (NASDAQ: HSII) gained 14.9 percent to $37.22 as the company posted upbeat results for its first quarter. Santander Consumer USA Holdings Inc. (NYSE: SC) shares climbed 14 percent to $17.90 following upbeat quarterly earnings. Helix Energy Solutions Group, Inc. (NYSE: HLX) climbed 14 percent to $7.12 following strong quarterly results. Check-Cap Ltd. (NASDAQ: CHEK) gained 13.6 percent to $8.25. Atossa Genetics Inc. (NASDAQ: ATOS) rose 11.8 percent to $3.34. Atossa Genetics disclosed that it has Received positive interim review from the Independent Safety Committee in Phase 1 Topical endoxifen dose escalation study in men. Cadence Design Systems, Inc. (NASDAQ: CDNS) gained 11.6 percent to $40.99 after the company posted upbeat Q1 results and issued a strong Q2 forecast. Genprex, Inc. (NASDAQ: GNPX) climbed 11.2 percent to $4.9363. Mitel Networks Corporation (NASDAQ: MITL) rose 10.5 percent to $11.23 after the company agreed to be acquired by affiliates of Searchlight Capital Partners for $2.0 billion. Systemax Inc. (NYSE: SYX) rose 10.2 percent to $30.86. Sidoti & Co. upgraded Systemax from Neutral to Buy. Orchids Paper Products Company (NYSE: TIS) surged 9.2 percent to $7.13. Orchids Paper Products is expected to report its Q1 financial results on Wednesday, April 25, 2018. New Oriental Education & Technology Group Inc. (NYSE: EDU) rose
  • [By Max Byerly]

    State of New Jersey Common Pension Fund D trimmed its position in shares of New Oriental (NYSE:EDU) by 11.5% during the 1st quarter, Holdings Channel reports. The institutional investor owned 148,379 shares of the company’s stock after selling 19,268 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in New Oriental were worth $13,005,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    New Oriental (NYSE: EDU) and The Graham (NYSE:GHC) are both consumer discretionary companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

  • [By Brian Stoffel]

    As the old saying goes, "You need to strike when the iron is hot."�Management at New Oriental Education & Technology Group�(NYSE:EDU), a provider of in-person and online after-school tutoring in China, knows that the business is red-hot right now; it is striking by leveraging its balance sheet and growing brand by pushing a massive expansion throughout the Middle Kingdom.

Top 10 Heal Care Stocks To Invest In Right Now: Madrigal Pharmaceuticals, Inc. (MDGL)

Advisors' Opinion:
  • [By Ethan Ryder]

    Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) have been assigned a consensus rating of “Buy” from the ten ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $159.86.

Top 10 Heal Care Stocks To Invest In Right Now: Oil States International Inc.(OIS)

Advisors' Opinion:
  • [By Joseph Griffin]

    Oil States International (NYSE: OIS) is one of 14 public companies in the “Oil & gas field machinery” industry, but how does it contrast to its peers? We will compare Oil States International to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, dividends, earnings and risk.

  • [By Matthew DiLallo]

    Shares of Oil States International, Inc. (NYSE:OIS) rallied on Thursday, rising�more than 14% by 2:45 p.m. EDT, after the company reported better-than-expected first-quarter results.

Top 10 Heal Care Stocks To Invest In Right Now: Consolidated Communications Holdings Inc.(CNSL)

Advisors' Opinion:
  • [By Ethan Ryder]

    Consolidated Communications (NASDAQ: CNSL) is one of 74 public companies in the “Telephone communication, except radio” industry, but how does it contrast to its peers? We will compare Consolidated Communications to related companies based on the strength of its analyst recommendations, profitability, earnings, dividends, institutional ownership, valuation and risk.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Consolidated Communications (CNSL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Heal Care Stocks To Invest In Right Now: Sony Corp Ord(SNE)

Advisors' Opinion:
  • [By Leo Sun]

    When Sony (NYSE:SNE) launched the PlayStation VR, or PSVR, in late 2016, the headset seemed to have a shot at bringing virtual reality to mainstream gamers. The company enjoyed a large customer base with the PS4, the most popular current-gen gaming console, and the PSVR was cheaper than other high-end VR headsets on the market.

  • [By Benzinga News Desk]

    Sony (NYSE: SNE) said it would pay about $2.3 billion to gain control of EMI, becoming the world’s largest music publisher in an industry that has found new life on the back of streaming services: Link

  • [By Stephan Byrd]

    Sony (NYSE: SNE) and Knowles (NYSE:KN) are both consumer discretionary companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Top 10 Heal Care Stocks To Invest In Right Now: Mitsubishi Heavy Industries Ltd (MHVYF)

Advisors' Opinion:
  • [By SEEKINGALPHA.COM]

    Major foreign competitors today now include the French firm Areva (OTCPK:ARVCF) and the Japanese firm Mitsubishi Heavy Industry (OTCPK:MHVYF). This is not a complete list but a focus on major players.

Tuesday, May 29, 2018

Top 10 Medical Stocks To Buy Right Now

tags:SHIP,PCH,ECOM ,NOAH,NWN,HEI,CVI,NBRV,FIBK,PRU,

Both in the U.S. and internationally, marijuana -- especially the medical variety -- is getting more and more accepted with time. So, how do you invest in it? In this episode of MarketFoolery, host Chris Hill talks with Motley Fool analyst Shannon Jones about how to get exposure to the fledgling industry without buying into the ever-risky penny stocks that make up most of the U.S. marijuana market.

Click play to learn about a few international companies for your marijuana stock watch list, as well as one domestic picks-and-shovels play; the exciting state of medical marijuana in the U.S. today; how growing acceptance of medical marijuana in the sports industry fits into changing views around the drug; and more.

A full transcript follows the video.

<div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><iframe src="https://fast.wistia.net/embed/iframe/mthypcys5f?videoFoam=true" title="Wistia video player" allowtransparency="true" frameborder="0" scrolling="no" class="wistia_embed" name="wistia_embed" allowfullscreen mozallowfullscreen webkitallowfullscreen oallowfullscreen msallowfullscreen width="100%" height="100%"></iframe></div></div> <script src="https://fast.wistia.net/assets/external/E-v1.js" async></script>

Top 10 Medical Stocks To Buy Right Now: Seanergy Maritime Holdings Corp(SHIP)

Advisors' Opinion:
  • [By Logan Wallace]

    Seanergy Maritime (NASDAQ: SHIP) and Euronav (NYSE:EURN) are both small-cap transportation companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Top 10 Medical Stocks To Buy Right Now: Potlatch Corporation(PCH)

Advisors' Opinion:
  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on PotlatchDeltic (PCH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    PotlatchDeltic (NASDAQ:PCH) was upgraded by equities researchers at Vertical Research to a “hold” rating in a research report issued on Monday, The Fly reports. The analysts noted that the move was a valuation call.

  • [By Stephan Byrd]

    Teachers Insurance & Annuity Association of America bought a new position in PotlatchDeltic (NASDAQ:PCH) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 78,505 shares of the real estate investment trust’s stock, valued at approximately $4,086,000. Teachers Insurance & Annuity Association of America owned approximately 0.19% of PotlatchDeltic at the end of the most recent reporting period.

Top 10 Medical Stocks To Buy Right Now: ChannelAdvisor Corporation(ECOM )

Advisors' Opinion:
  • [By Shane Hupp]

    ChannelAdvisor (NYSE: ECOM) and Tyler Technologies (NYSE:TYL) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Top 10 Medical Stocks To Buy Right Now: Noah Holdings Ltd.(NOAH)

Advisors' Opinion:
  • [By Joseph Griffin]

    Noah Coin (CURRENCY:NOAH) traded up 4% against the US dollar during the 1 day period ending at 23:00 PM E.T. on May 18th. During the last seven days, Noah Coin has traded down 6.4% against the US dollar. One Noah Coin token can now be purchased for about $0.0079 or 0.00000096 BTC on exchanges. Noah Coin has a market cap of $0.00 and $4.58 million worth of Noah Coin was traded on exchanges in the last day.

  • [By Max Byerly]

    Noah Holdings (NYSE:NOAH)’s share price hit a new 52-week high and low on Monday . The stock traded as low as $57.81 and last traded at $57.76, with a volume of 191661 shares traded. The stock had previously closed at $54.50.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers Petróleo Brasileiro S.A. - Petrobras (NYSE: PBR) fell 13.2 percent to $10.95 in pre-market trading after dropping 1.33 percent on Friday. Banco Santander, S.A. (NYSE: SAN) shares fell 8.7 percent to $5.33 in pre-market trading after declining 2.83 percent on Friday. Synchrony Financial (NYSE: SYF) fell 8 percent to $32.75 in the pre-market trading session. AerCap Holdings N.V. (NYSE: AER) shares fell 7.4 percent to $51.17 in pre-market trading. Inovio Pharmaceuticals, Inc. (NASDAQ: INO) fell 7.4 percent to $4.54 in pre-market trading. Tailored Brands, Inc. (NYSE: TLRD) fell 7 percent to $31.83 in pre-market trading. California Resources Corporation (NYSE: CRC) shares fell 6.5 percent to $30.29 in pre-market trading after dropping 10.60 percent on Friday. Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) fell 6.2 percent to $6.85 in pre-market trading. RedHill Biopharma Ltd. (NASDAQ: RDHL) fell 6 percent to $6.67 in pre-market trading. QEP Resources, Inc. (NYSE: QEP) shares fell 5.8 percent to $11.45 in pre-market trading after dropping 6.75 percent on Friday. Noah Holdings Limited (NYSE: NOAH) fell 5.5 percent to $61.53 in pre-market trading. CNH Industrial N.V. (NYSE: CNHI) shares fell 5.2 percent to $11.70 in pre-market trading

Top 10 Medical Stocks To Buy Right Now: Northwest Natural Gas Company(NWN)

Advisors' Opinion:
  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Northwest Natural Gas (NWN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Northwest Natural Gas (NWN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    NW Natural (NYSE:NWN) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

Top 10 Medical Stocks To Buy Right Now: Heico Corporation(HEI)

Advisors' Opinion:
  • [By Shane Hupp]

    HEICO Corp (NYSE:HEI) shares hit a new 52-week high and low during mid-day trading on Monday . The company traded as low as $93.55 and last traded at $92.05, with a volume of 2840 shares changing hands. The stock had previously closed at $93.16.

  • [By Lisa Levin]

     

    Companies Reporting After The Bell SpartanNash Company (NASDAQ: SPTN) is projected to post quarterly earnings at $0.53 per share on revenue of $2.38 billion. HP Inc. (NYSE: HPQ) is expected to post quarterly earnings at $0.48 per share on revenue of $13.57 billion. salesforce.com, inc. (NYSE: CRM) is projected to post quarterly earnings at $0.47 per share on revenue of $2.94 billion. HEICO Corporation (NYSE: HEI) is estimated to post quarterly earnings at $0.53 per share on revenue of $424.96 million. Safe Bulkers, Inc. (NYSE: SB) is expected to post quarterly earnings at $0.02 per share on revenue of $41.10 million
  • [By ]

    HEICO (HEI) : "We're not buying anything at a 52-week high -- but on a pullback, you bet."

    Cramer and the AAP team say the main factor contributing to Friday's weakness was Apple (AAPL) . Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By ]

    In the Lightning Round, Cramer was bullish on Align Technology (ALGN) , Regions Financial (RF) , Edwards Lifesciences (EW) , Qualys (QLYS) and HEICO (HEI) .

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Heico (HEI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Medical Stocks To Buy Right Now: CVR Energy Inc.(CVI)

Advisors' Opinion:
  • [By Stephan Byrd]

    CVR Energy Inc. (NYSE:CVI) reached a new 52-week high and low during trading on Wednesday . The stock traded as low as $41.88 and last traded at $41.81, with a volume of 8024 shares trading hands. The stock had previously closed at $41.64.

  • [By Stephan Byrd]

    CVR Energy Inc. (NYSE:CVI) shares hit a new 52-week high and low during mid-day trading on Monday . The stock traded as low as $39.74 and last traded at $39.69, with a volume of 566335 shares traded. The stock had previously closed at $36.81.

Top 10 Medical Stocks To Buy Right Now: Nabriva Therapeutics AG(NBRV)

Advisors' Opinion:
  • [By Ethan Ryder]

    Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.23. Nabriva Therapeutics had a negative return on equity of 79.30% and a negative net margin of 600.34%. The firm had revenue of $7.55 million for the quarter, compared to analyst estimates of $1.27 million. equities analysts anticipate that Nabriva Therapeutics will post -1.9 EPS for the current fiscal year.

  • [By Lisa Levin]

    Shares of Nabriva Therapeutics plc (NASDAQ: NBRV) were down 14 percent to $4.6666 despite positive topline results from Phase 3 Lefamulin trial.

    Carver Bancorp, Inc. (NASDAQ: CARV) was down, falling around 21 percent to $6.59 after surging 201.37 percent on Thursday.

  • [By Chris Lange]

    Nabriva Therapeutics PLC (NASDAQ: NBRV) watched its shares take a step back on Monday’s despite seeing positive results in its late-stage pneumonia trial. The stock was actually up about 17% before the markets opened, but this quickly reversed. The results come from the firm��s lefamulin evaluation against pneumonia (LEAP 2) Phase 3 clinical trial.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers Natural Health Trends Corp (NASDAQ: NHTC) fell 7.8 percent to $19.80 in pre-market trading after rising 1.46 percent on Friday. Endocyte, Inc. (NASDAQ: ECYT) shares fell 6.6 percent to $11.41 in pre-market trading after climbing 4.18 percent on Friday. Quorum Health Corporation (NYSE: QHC) shares fell 6.2 percent to $5.15 in pre-market trading after tumbling 11.45 percent on Friday. Arcadia Biosciences, Inc. (NASDAQ: RKDA) fell 6.1 percent to $7.31 in pre-market trading after declining 3.35 percent on Friday. Boston Scientific Corporation (NYSE: BSX) fell 5.6 percent to $28.30 in pre-market trading. Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 5.3 percent to $6.06 in pre-market trading after gaining 2.73 percent on Friday. Xerox Corporation (NYSE: XRX) shares fell 5.2 percent to $28.60 in pre-market trading. Xerox terminated its transaction agreement with Fujifilm and entered into a new agreement with Carl Icahn and Darwin Deason. JP Morgan downgraded Xerox from Overweight to Neutral. Cellcom Israel Ltd. (NYSE: CEL) fell 5.2 percent to $7.02 in pre-market trading. Cellcom is expected to release Q1 results on May 30, 2018. Perrigo Company plc (NYSE: PRGO) fell 4.5 percent to $74 in pre-market trading. Nabriva Therapeutics plc (NASDAQ: NBRV) shares fell 4 percent to $4.66 in pre-market trading

Top 10 Medical Stocks To Buy Right Now: First Interstate BancSystem Inc.(FIBK)

Advisors' Opinion:
  • [By Shane Hupp]

    Get a free copy of the Zacks research report on First Interstate BancSystem (FIBK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Massachusetts Financial Services Co. MA lifted its stake in shares of First Interstate BancSystem (NASDAQ:FIBK) by 4.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 464,152 shares of the financial services provider’s stock after acquiring an additional 20,543 shares during the period. Massachusetts Financial Services Co. MA owned 0.82% of First Interstate BancSystem worth $18,357,000 as of its most recent SEC filing.

Top 10 Medical Stocks To Buy Right Now: Prudential Financial Inc.(PRU)

Advisors' Opinion:
  • [By Zacks]

    Well, given the growing demand for securitized mortgage deals, Barclays plans to package and sell these Irish loans over the next two months. The group of investors that has shown interest in buying residential mortgage backed securities includes M&G Investments, the investment management division of British insurer Prudential Plc (NYSE: PRU) and Pacific Investment Management Co. ("PIMCO").

  • [By Jason Hall, Chuck Saletta, and Reuben Gregg Brewer]

    But that doesn't mean you need to make risky bets to capture solid returns, either, and buying solid companies at reasonable prices can help create a margin of safety and improve your returns, while also decreasing your risk of permanent losses. Three stocks that meet these criteria are small healthcare real-estate specialist�Caretrust REIT Inc�(NASDAQ:CTRE), financial services giant�Prudential Financial Inc�(NYSE:PRU), and energy behemoth�ExxonMobil Corporation�(NYSE:XOM).�

  • [By Max Byerly]

    Flippin Bruce & Porter Inc. grew its holdings in shares of Prudential Financial (NYSE:PRU) by 2.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 61,363 shares of the financial services provider’s stock after acquiring an additional 1,391 shares during the period. Flippin Bruce & Porter Inc.’s holdings in Prudential Financial were worth $6,354,000 as of its most recent SEC filing.

  • [By Chuck Saletta]

    Prudential Financial (NYSE:PRU) takes such pride in its rock-solid financial condition that it uses an actual rock -- the Rock of Gibraltar�-- as its corporate symbol. Prudential Financial backs up that claim with a balance sheet that has more cash, cash equivalents, and short-term investments�than total debt on it. It also claims a debt-to-equity ratio around 0.6 and a current ratio around 1.0�, which are further signs of a solid financial condition.

Sunday, May 27, 2018

How Much Does Warren Buffett Get From Social Security?

Warren Buffett is one of the wealthiest people in the world, with a stake in Berkshire Hathaway that's worth tens of billions of dollars. Buffett is just about the last person who needs the financial support that Social Security provides to retirees, but the Social Security program doesn't have any limits based on a recipient's financial means.

At age 87, Buffett has been eligible to receive Social Security for a long time. Thanks to the highly predictable way in which the Berkshire CEO gets paid, it's possible to run the numbers and get a rough idea of how much the Oracle of Omaha should be eligible to receive from Social Security.

Warren Buffett, with some people out of focus behind him.

Image source: The Motley Fool.

Why you can guess what Buffett gets from Social Security

The reason why it's possible to get an idea of what Buffett gets in Social Security benefits is that the Social Security Administration bases its monthly retirement payments on a person's career earnings. The SSA looks at a person's 35 top-earning years after adjusting each annual amount for inflation, and it then calculates what's known as average indexed monthly earnings. From there, the figure goes through an SSA formula that determines a person's primary insurance amount. That's the base amount that a retiree is entitled to receive at full retirement age, but the actual payment can be higher or lower depending on whether the person claims benefits later or earlier than full retirement age.

Buffett has been very public in revealing his salaries over the years. In Berkshire's proxy statement for its annual meeting in 1999, the company revealed that Buffett had earned $100,000 each year for the past 18 years, dating back to 1981. That practice has continued to the present day.

Prior to that, reports are somewhat less complete. However, some secondary sources refer to Buffett getting a smaller $50,000 salary from Berkshire for at least a couple of years prior to 1981. Others point to Buffett's initial job working for Ben Graham's partnership, receiving a starting salary of $12,000 a year in 1954.

Fortunately, it's not necessary to know exactly how much Buffett made in order to calculate what he probably gets from Social Security. That's because the SSA has already done it for us, because Buffett is one of a select few people who has consistently earned more than the maximum amount on which Social Security charges payroll taxes. It wasn't until 2008 that the wage base limit on Social Security exceeded Buffett's $100,000 Berkshire salary, thus guaranteeing that for at least 28 years, Buffett earned the maximum amount. A $12,000 salary in the 1950s would have been well above the wage limit for Social Security at that time, as would a $50,000 salary in the 1970s. It's therefore reasonable to assume that Buffett's earnings record entitles him to the maximum benefit.

The choices Buffett would have had

Like anyone, Buffett had to choose when to take Social Security benefits. If he'd claimed at the earliest available age of 62 back in 1992, then the maximum initial monthly payment would have been $860 per month. Thanks to cost of living adjustments along the way, that number would work out to $1,527 per month in Social Security benefits today.

Based on his birth year of 1930, Buffett's full retirement age was 65. If he waited until then before claiming benefits, then he would have gotten an initial monthly amount of $1,199 in 1995. That would have grown to $1,961 per month today.

Yet Buffett didn't really have much need to collect Social Security, and so it would have been reasonable for him to wait until the latest possible age of 70 before claiming. If he did so, then he would have been entitled to an initial monthly benefit of $1,752 in 2000. Over the following 18 years, cost of living adjustments would have boosted that amount to $2,562 per month.

The interesting thing about Buffett and Social Security

Buffett has ideas about dealing with Social Security's financial issues. One solution he's suggested has been to eliminate the wage base limit on Social Security taxes, thereby increasing the amount of revenue that the program brings in. In particular, those executives who make millions of dollars in salaries and other compensation would see the amount they had to pay into Social Security through payroll taxes skyrocket.

Yet what's somewhat ironic about that idea is that Buffett wouldn't have had to pay markedly more in payroll taxes under his proposal. Taxes on the full $100,000 would have amounted to $6,200 annually since 1990, with lower tax rates having applied in earlier years. Yet because he kept his salary low compared to his peers, he never would've had to pay the gargantuan taxes that executives with seven- or eight-figure salaries would pay under his proposal.

It's amusing to think of the billionaire investor getting a $2,562 check from Social Security deposited into his bank account every month. Yet Buffett's experience shows how every worker, rich or poor, stands to benefit from the Social Security program.

Saturday, May 26, 2018

Best Buy (BBY) Issues Q2 Earnings Guidance

Best Buy (NYSE:BBY) issued an update on its second quarter earnings guidance on Thursday morning. The company provided EPS guidance of $0.77-0.82 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.81. The company issued revenue guidance of $9.1-9.2 billion, compared to the consensus revenue estimate of $9.00 billion.Best Buy also updated its FY19 guidance to $4.80-5.00 EPS.

Shares of BBY stock opened at $70.90 on Friday. Best Buy has a one year low of $51.61 and a one year high of $79.90. The company has a market capitalization of $21.41 billion, a P/E ratio of 16.04, a P/E/G ratio of 1.07 and a beta of 0.91. The company has a current ratio of 1.26, a quick ratio of 0.59 and a debt-to-equity ratio of 0.22.

Get Best Buy alerts:

Best Buy (NYSE:BBY) last posted its quarterly earnings results on Thursday, May 24th. The technology retailer reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.08. The firm had revenue of $9.11 billion for the quarter, compared to analysts’ expectations of $8.75 billion. Best Buy had a return on equity of 32.68% and a net margin of 2.37%. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.60 EPS. sell-side analysts anticipate that Best Buy will post 4.98 EPS for the current fiscal year.

A number of equities analysts have issued reports on BBY shares. Zacks Investment Research upgraded Best Buy from a hold rating to a strong-buy rating and set a $84.00 price target on the stock in a report on Friday, February 2nd. Barclays increased their price target on Best Buy from $80.00 to $85.00 and gave the stock an overweight rating in a report on Tuesday, January 30th. ValuEngine upgraded Best Buy from a hold rating to a buy rating in a report on Friday, February 2nd. Piper Jaffray Companies increased their price target on Best Buy from $68.00 to $83.00 and gave the stock an overweight rating in a report on Monday, February 26th. Finally, Citigroup restated a neutral rating and set a $74.00 price target (up from $69.00) on shares of Best Buy in a report on Friday, February 16th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Best Buy has an average rating of Hold and an average price target of $71.50.

In related news, insider Patricia H. Walker sold 1,569 shares of the stock in a transaction on Monday, March 19th. The stock was sold at an average price of $68.72, for a total value of $107,821.68. Following the completion of the sale, the insider now directly owns 35,552 shares of the company’s stock, valued at approximately $2,443,133.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Shari L. Ballard sold 3,475 shares of the stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $72.45, for a total value of $251,763.75. Following the completion of the sale, the insider now directly owns 116,785 shares of the company’s stock, valued at $8,461,073.25. The disclosure for this sale can be found here. Over the last quarter, insiders sold 365,639 shares of company stock worth $25,651,834. 0.75% of the stock is owned by company insiders.

About Best Buy

Best Buy Co, Inc operates as a retailer of technology products, services, and solutions in the United States, Canada, and Mexico. The company operates in two segments, Domestic and International. Its stores provide consumer electronics, including digital imaging, health and fitness, home automation, home theater, and portable audio products; computing and mobile phones, such as computing and peripherals, networking products, tablets, smart watches, and e-readers, as well as mobile phones comprising related mobile network carrier commissions; and entertainment products, including drones, movies, music, and technology toys, as well as gaming hardware and software, and virtual reality and other software products.

Earnings History and Estimates for Best Buy (NYSE:BBY)